Akhil Santhosh: Pembrolizumab and lenvatinib show promise in mesothelioma treatment

Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared a post on X:

“Pembrolizumab + lenvatinib has encouraging responses in malignant mesothelioma patients as second line post-progression on nivo-ipi in the PEMMELA 2 trial.”